Who are Repatha's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Praluent (Alirocumab), Repatha®, LEQVIO, Evolocumab combined with statins, Evolocumab Prefilled Syringe, SYH2053/placebo injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/evolocumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Repatha — Competitive Intelligence Brief

Repatha (EVOLOCUMAB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PCSK9 Inhibitor [EPC]. Area: Metabolic.

marketed PCSK9 Inhibitor [EPC] PCSK9 Metabolic Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Repatha (EVOLOCUMAB) — Repatha. Evolocumab, a human monoclonal IgG2, lowers LDL-C by inhibiting PCSK9 binding to LDLR, increasing LDLR availability to clear LDL.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Repatha TARGET	EVOLOCUMAB	Repatha	marketed	PCSK9 Inhibitor [EPC]	PCSK9	2015-01-01
Praluent (Alirocumab)	Praluent (Alirocumab)	Federico II University	marketed	PCSK9 inhibitor (monoclonal antibody)	PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9)
Repatha®	Repatha®	Sejong General Hospital	marketed	PCSK9 inhibitor (monoclonal antibody)	PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9)
LEQVIO	LEQVIO	University of Louisville	marketed	PCSK9 inhibitor (siRNA)	PCSK9 mRNA
Evolocumab combined with statins	Evolocumab combined with statins	Zibo Central Hospital	marketed	PCSK9 inhibitor (monoclonal antibody)	PCSK9
Evolocumab Prefilled Syringe	Evolocumab Prefilled Syringe	University of Erlangen-Nürnberg Medical School	marketed	PCSK9 inhibitor (monoclonal antibody)	PCSK9
SYH2053/placebo injection	SYH2053/placebo injection	CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.	phase 3	PCSK9 inhibitor	PCSK9

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PCSK9 Inhibitor [EPC] class)

Repatha · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Repatha — Competitive Intelligence Brief. https://druglandscape.com/ci/evolocumab. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab